We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Midlife Lipid and Glucose Levels Are Associated With Alzheimer's Disease

By LabMedica International staff writers
Posted on 30 Mar 2022
Print article
Image: Midlife lipid and glucose levels are associated with Alzheimer\'s disease (Photo courtesy of Stanford Blood Center)
Image: Midlife lipid and glucose levels are associated with Alzheimer\'s disease (Photo courtesy of Stanford Blood Center)

Alzheimer's disease (AD) is the fifth leading cause of death among Americans 65 years of age or older, with a prevalence of 5.8 million cases. This number is projected to nearly triple to 14 million people by 2060.

Individuals with AD commonly exhibit features of cerebrovascular disease in combination with amyloid beta (Aβ) and tau neuropathology. Genetic studies of AD have identified common and rare variants associated with AD in genes involved in lipoprotein metabolism and processing related to AD.

Medical Scientists at the Boston University School of Medicine (Boston, MA, USA) and their colleagues looked at the influence of vascular risk factors on incident Alzheimer's dementia over time among Framingham Heart Study Offspring participants, a group that's been evaluated since 1971. A total of 271 participants (167 women, 104 men) diagnosed with Alzheimer's dementia were included in the analysis as cases. Of these, 225 people were without stroke, 24 people had Alzheimer's and stroke, and 24 people had mixed Alzheimer's and vascular dementia. People with a diagnosis of non-Alzheimer's dementia were excluded. Controls included 4,867 cognitively normal participants.

Data on lipid fractions, glucose, blood pressure, BMI, and smoking were obtained prospectively from participants across nine quadrennial examinations. Age-, sex-, and education-adjusted models were tested for each risk factor measured at each exam and within three adult age groups: early adults (ages 35 to 50, median 41), middle adults (ages 51 to 60, median 54), and late adults (ages 61 to 70, median 63.5). Mean follow-up periods for people in the early, middle, and late age groups were 35.2 years, 25.8 years, and 18.5 years, respectively.

The team reported that as participants grew older, they tended to have higher triglyceride and glucose levels, higher systolic and diastolic blood pressure, and lower HDL cholesterol levels. They also were more likely to be treated for diabetes, hypertension, and dyslipidemia. Incident Alzheimer's dementia was negatively associated with HDL cholesterol for every 15 mg/dL increase in early adulthood (Hazard Ratio [HR] 0.85) and in middle adulthood (HR 0.82). This association remained significant with a similar effect size in the middle adulthood group when adjusted for dyslipidemia treatment.

The analyses also showed: triglyceride levels were associated with Alzheimer's dementia only in the early adulthood group, before (HR 1.33) and after (HR 1.30) adjusting for dyslipidemia treatment. Blood glucose in middle adulthood was associated with Alzheimer's dementia per 15 mg/dL increase, before (HR 1.15) and after (HR 1.18) adjusting for diabetes treatment. Future development of Alzheimer's dementia was progressively higher and likely to occur earlier among people who had blood glucose in pre-diabetic (100 to 126 mg/dL) and diabetic (>126 mg/dL) ranges in early adulthood and middle adulthood.

The authors concluded that HDL-C, triglyceride, and glucose levels measured in early to middle adulthood are significantly associated with incident AD several decades later, which suggests that early intervention to maintain healthy HDL, triglyceride, and glucose levels may improve cognition and lower AD risk in addition to the benefits of promoting vascular and metabolic health. The study was published on March 23, 2022 in the journal Alzheimer's & Dementia.

Related Links:
Boston University School of Medicine

Automated ELISA-IFA-BLOT Processor AP 22
New
Gold Supplier
SARS-CoV-2 Antigen Rapid Test
RapiSafe SARS-CoV-2 Antigen Rapid Test (Professional use)
New
Gold Supplier
Auto Urinary Sediment Analyzer
EH-2030
New
Modular Sequencing Workstation
MGIFLP-L200

Print article

Channels

Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more

Industry

view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.